Prevalence of protective hepatitis B surface antibody levels and associated factors among women admitted for delivery at Kawempe National Referral Hospital, Uganda: A cross-sectional study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Mother-to-child transmission sustains the burden of hepatitis B virus (HBV) infection in sub-Saharan Africa, yet little is known about whether women giving birth in Uganda are protected. We estimated the prevalence of protective hepatitis B surface antibody (anti-HBs) levels, described serological profiles and identified associated factors among women admitted for delivery at Kawempe National Referral Hospital, Kampala. In this cross-sectional study, 418 women were selected by systematic random sampling in 2024 and interviewed about socio-demographic characteristics, hepatitis B testing, vaccination and exposures. Anti-HBs was quantified by electrochemiluminescence immunoassay (protective: ≥10 mIU/mL); other HBV markers were screened with a rapid test. Prevalence ratios were estimated with modified Poisson regression. Overall, 264 women (63.2%) reported vaccination: 203 during the current pregnancy and 61 before it only. Protective levels were found in 322 women (77.0%; 95% confidence interval [CI] 72.8–80.8): 50.6% of never-vaccinated women, 82.0% of those vaccinated before the current pregnancy only and 95.6% of those vaccinated during it. After adjustment, vaccination before the current pregnancy only (adjusted prevalence ratio 1.54; 95% CI 1.24–1.89) and during it (1.86; 95% CI 1.57–2.20) were associated with protection; no socio-demographic or behavioural factor was. Eighty-two women (19.6%) had no serological evidence of immunity or infection; 65 had never been vaccinated. Of 300 women who reported a previous negative test, 50 (16.7%) had never been vaccinated, and 68 of 250 vaccinated women with known completion status (27.2%) had not completed three doses, mostly because they were not told to return or forgot. The rapid test detected hepatitis B surface antigen in 21 women (5.0%), but discordant marker patterns suggest some false positives. One in five women reached delivery susceptible to HBV, largely because a negative test was not followed by vaccination. Linking every negative antenatal test to vaccination could close much of this gap.

Article activity feed